- Home
- BKYI vs PPBT Comparison
BKYI vs PPBT Comparison
Compare BKYI & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- PPBT
- Stock Information
- Founded
- BKYI 1993
- PPBT 2010
- Country
- BKYI United States
- PPBT Israel
- Employees
- BKYI N/A
- PPBT N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- BKYI Technology
- PPBT Health Care
- Exchange
- BKYI Nasdaq
- PPBT Nasdaq
- Market Cap
- BKYI 5.3M
- PPBT 5.5M
- IPO Year
- BKYI 1997
- PPBT N/A
- Fundamental
- Price
- BKYI $0.75
- PPBT $0.58
- Analyst Decision
- BKYI
- PPBT Strong Buy
- Analyst Count
- BKYI 0
- PPBT 1
- Target Price
- BKYI N/A
- PPBT $33.00
- AVG Volume (30 Days)
- BKYI 139.1K
- PPBT 408.1K
- Earning Date
- BKYI 11-13-2025
- PPBT 11-14-2025
- Dividend Yield
- BKYI N/A
- PPBT N/A
- EPS Growth
- BKYI N/A
- PPBT N/A
- EPS
- BKYI N/A
- PPBT N/A
- Revenue
- BKYI $6,911,148.00
- PPBT N/A
- Revenue This Year
- BKYI $7.45
- PPBT N/A
- Revenue Next Year
- BKYI $23.29
- PPBT N/A
- P/E Ratio
- BKYI N/A
- PPBT N/A
- Revenue Growth
- BKYI N/A
- PPBT N/A
- 52 Week Low
- BKYI $0.52
- PPBT $0.53
- 52 Week High
- BKYI $3.68
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- BKYI 46.17
- PPBT 19.96
- Support Level
- BKYI $0.71
- PPBT $0.57
- Resistance Level
- BKYI $0.81
- PPBT $0.62
- Average True Range (ATR)
- BKYI 0.04
- PPBT 0.03
- MACD
- BKYI 0.00
- PPBT 0.06
- Stochastic Oscillator
- BKYI 35.10
- PPBT 45.09
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.